Abstract
Brolucizumab (Beovu) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
